Cargando…

Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador

Neuroendocrine tumors (NETs) represent a heterogeneous malignancy group of neoplasms, with a limited amount of data from Latin America. Thus, this observational study aimed to provide data about the prevalence, incidence, and survival rates for NET in Ecuadorian hospitals. The study was conducted us...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar, Karime Montes, Vicente-Villardon, Jose Luis, Villacís Gonzalez, Rosa Elisa, Castillo Cordova, Paul Humberto, Sánchez Rodríguez, Johanna Mabel, De la Cruz-Velez, Melina, Siteneski, Aline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408119/
https://www.ncbi.nlm.nih.gov/pubmed/36011226
http://dx.doi.org/10.3390/healthcare10081569
_version_ 1784774529279590400
author Escobar, Karime Montes
Vicente-Villardon, Jose Luis
Villacís Gonzalez, Rosa Elisa
Castillo Cordova, Paul Humberto
Sánchez Rodríguez, Johanna Mabel
De la Cruz-Velez, Melina
Siteneski, Aline
author_facet Escobar, Karime Montes
Vicente-Villardon, Jose Luis
Villacís Gonzalez, Rosa Elisa
Castillo Cordova, Paul Humberto
Sánchez Rodríguez, Johanna Mabel
De la Cruz-Velez, Melina
Siteneski, Aline
author_sort Escobar, Karime Montes
collection PubMed
description Neuroendocrine tumors (NETs) represent a heterogeneous malignancy group of neoplasms, with a limited amount of data from Latin America. Thus, this observational study aimed to provide data about the prevalence, incidence, and survival rates for NET in Ecuadorian hospitals. The study was conducted using data from the Society for the Fight Against Cancer (SOLCA). We evaluated patients with NETs (2000–2020) using the HJ-Biplot method and Cox proportional hazards. Annual age-adjusted incidence and limited-duration prevalence in multivariable analyses as well as hazard ratios (HRs) for mortality and survival were obtained. In the years 2000–2020, the age-adjusted incidence rate increased by 9-fold in the stomach and by 7-fold in the breast. The incidence rates were 1.38 per 100,000 persons in the lung and at 1.79 per 100,000 persons in gastroenteropancreatic sites (rectum, stomach, and pancreas). The prevalence increased from 0.0027% in 2000 to 0.0736% in 2019 and 0.0245% in 2020. Overall survival was worse for metastatic NETs (HR, 4.061; 95% CI, 1.932–8.540; p < 0.001) and advanced local NETs (HR, 2.348; 95% CI, 1.007–5.475 p < 0.048) than for localized NETs. In conclusion, the NET incidence increased in the last 20 years and survival decreased over time, especially for metastatic tumors in the pancreas and the nostril.
format Online
Article
Text
id pubmed-9408119
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94081192022-08-26 Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador Escobar, Karime Montes Vicente-Villardon, Jose Luis Villacís Gonzalez, Rosa Elisa Castillo Cordova, Paul Humberto Sánchez Rodríguez, Johanna Mabel De la Cruz-Velez, Melina Siteneski, Aline Healthcare (Basel) Article Neuroendocrine tumors (NETs) represent a heterogeneous malignancy group of neoplasms, with a limited amount of data from Latin America. Thus, this observational study aimed to provide data about the prevalence, incidence, and survival rates for NET in Ecuadorian hospitals. The study was conducted using data from the Society for the Fight Against Cancer (SOLCA). We evaluated patients with NETs (2000–2020) using the HJ-Biplot method and Cox proportional hazards. Annual age-adjusted incidence and limited-duration prevalence in multivariable analyses as well as hazard ratios (HRs) for mortality and survival were obtained. In the years 2000–2020, the age-adjusted incidence rate increased by 9-fold in the stomach and by 7-fold in the breast. The incidence rates were 1.38 per 100,000 persons in the lung and at 1.79 per 100,000 persons in gastroenteropancreatic sites (rectum, stomach, and pancreas). The prevalence increased from 0.0027% in 2000 to 0.0736% in 2019 and 0.0245% in 2020. Overall survival was worse for metastatic NETs (HR, 4.061; 95% CI, 1.932–8.540; p < 0.001) and advanced local NETs (HR, 2.348; 95% CI, 1.007–5.475 p < 0.048) than for localized NETs. In conclusion, the NET incidence increased in the last 20 years and survival decreased over time, especially for metastatic tumors in the pancreas and the nostril. MDPI 2022-08-18 /pmc/articles/PMC9408119/ /pubmed/36011226 http://dx.doi.org/10.3390/healthcare10081569 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Escobar, Karime Montes
Vicente-Villardon, Jose Luis
Villacís Gonzalez, Rosa Elisa
Castillo Cordova, Paul Humberto
Sánchez Rodríguez, Johanna Mabel
De la Cruz-Velez, Melina
Siteneski, Aline
Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador
title Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador
title_full Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador
title_fullStr Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador
title_full_unstemmed Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador
title_short Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador
title_sort neuroendocrine tumors: an analysis of prevalence, incidence, and survival in a hospital-based study in ecuador
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408119/
https://www.ncbi.nlm.nih.gov/pubmed/36011226
http://dx.doi.org/10.3390/healthcare10081569
work_keys_str_mv AT escobarkarimemontes neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador
AT vicentevillardonjoseluis neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador
AT villacisgonzalezrosaelisa neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador
AT castillocordovapaulhumberto neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador
AT sanchezrodriguezjohannamabel neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador
AT delacruzvelezmelina neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador
AT siteneskialine neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador